Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.56 |
| ▸ | THRB | P10828 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23930402 | 0.87 | NLRP3 (0.56) | NLRP3THRBPOLBMAPTHSD17B10 | |
| SCHEMBL30193539 | 0.87 | NLRP3 (0.62) | NLRP3THRBPOLBMAPTRXFP1 | |
| SCHEMBL25771170 | 0.86 | NLRP3 (0.56) | NLRP3THRBPOLBMAPTHSD17B10 | |
| SCHEMBL30193720 | 0.85 | NLRP3 (0.64) | NLRP3THRBPOLBMAPTRXFP1 | |
| SCHEMBL25771193 | 0.84 | NLRP3 (0.65) | NLRP3THRBPOLBMAPTHSD17B10 | |
| SCHEMBL30193610 | 0.84 | NLRP3 (0.54) | NLRP3THRBPOLBMAPTHSD17B10 | |
| SCHEMBL30193556 | 0.84 | NLRP3 (0.54) | NLRP3THRBPOLBMAPTHSD17B10 | |
| SCHEMBL25285918 | 0.83 | NLRP3 (0.49) | NLRP3THRBMAPTTP53 | |
| SCHEMBL25771189 | 0.82 | NLRP3 (0.54) | NLRP3THRBPOLBMAPTHSD17B10 | |
| SCHEMBL25771187 | 0.80 | NLRP3 (0.55) | NLRP3THRBPOLBMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203064-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | NLRP3, NLRP1, NOD1 | NLRP3 1/4885THRB 2315/4885POLB 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.